Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...
1d
GlobalData on MSNNovartis and Dawn Health introduce breast cancer support appInitially launching in Germany, the app will soon be available in the UK, Australia, Canada, and other markets.
Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...
Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter. Fourth-quarter net ...
2d
Zacks.com on MSNNovartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results